Wei Zhang

Prof. Wei Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 July 2022 in Frontiers in Medicine
Verified
Journal Article
Open access
ZZZhipeng Zheng
Zhipeng Zheng
JTJingyi Tang
Jingyi Tang
YHYingnan Hu
Yingnan Hu
WZWei Zhang
Wei Zhang
The gastrointestinal (GI) tract harbors trillions of commensal microbes, called the gut microbiota, which plays a significant role in the regulation of GI physiology, particularly GI motility. The GI tract expresses an array of receptors, such as toll-like receptors (TLRs), G-protein coupled receptors, aryl hydrocarbon receptor (AhR), and ligand-gated ion channels, that sense different gut microbiota-derived bioactive substances. Specifically, microbial cell wall components and metabolites, including lipopeptides, peptidoglycan, lipopolysaccharides (LPS), bile acids (BAs), short-chain fatty acids (SCFAs), and tryptophan metabolites, mediate the effect of gut microbiota on GI motility through their close interactions with the enteroendocrine system, enteric nervous system, intestinal smooth muscle, and immune system. In turn, GI motility affects the colonization within the gut microbiota. However, the mechanisms by which gut microbiota interacts with GI motility remain to be elucidated. Deciphering the underlying mechanisms is greatly important for the prevention or treatment of GI dysmotility, which is a complication associated with many GI diseases, such as irritable bowel syndrome (IBS) and constipation. In this perspective, we overview the current knowledge on the role of gut microbiota and its metabolites in the regulation of GI motility, highlighting the potential mechanisms, in an attempt to provide valuable clues for the development of gut microbiota-dependent therapy to improve GI motility.

29 February 2024 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
YHYingnan Hu
Yingnan Hu
JTJingyi Tang
Jingyi Tang
YXYongfeng Xie
Yongfeng Xie
WXWenjun Xu
Wenjun Xu
WZWeihan Zhu
Weihan Zhu
WZWei Zhang
Wei Zhang

28 February 2023 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
ZZZhipeng Zheng
Zhipeng Zheng
YHYingnan Hu
Yingnan Hu
JTJingyi Tang
Jingyi Tang
WXWenjun Xu
Wenjun Xu
WZWeihan Zhu
Weihan Zhu
WZWei Zhang
Wei Zhang
Recovery from gastrointestinal (GI) surgery is often interrupted by the unpredictable occurrence of postoperative complications, including infections, anastomotic leak, GI dysmotility, malabsorption, cancer development, and cancer recurrence, in which the implication of gut microbiota is beginning to emerge. Gut microbiota can be imbalanced before surgery due to the underlying disease and its treatment. The immediate preparations for GI surgery, including fasting, mechanical bowel cleaning, and antibiotic intervention, disrupt gut microbiota. Surgical removal of GI segments also perturbs gut microbiota due to GI tract reconstruction and epithelial barrier destruction. In return, the altered gut microbiota contributes to the occurrence of postoperative complications. Therefore, understanding how to balance the gut microbiota during the perioperative period is important for surgeons. We aim to overview the current knowledge to investigate the role of gut microbiota in recovery from GI surgery, focusing on the crosstalk between gut microbiota and host in the pathogenesis of postoperative complications. A comprehensive understanding of the postoperative response of the GI tract to the altered gut microbiota provides valuable cues for surgeons to preserve the beneficial functions and suppress the adverse effects of gut microbiota, which will help to enhance recovery from GI surgery.

24 August 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
ZZZhipeng Zheng
Zhipeng Zheng
SWshuai Wang
shuai Wang
CWChenghao Wu
Chenghao Wu
YCYang Cao
Yang Cao
QGQiao Gu
Qiao Gu
WHwei Hu
wei Hu
Traumatic brain injury (TBI) is a common cause of disability and mortality, affecting millions of people every year. The neuroinflammation and immune response post-TBI initially have neuroprotective and reparative effects, but prolonged neuroinflammation leads to secondary injury and increases the risk of chronic neurodegenerative diseases. Persistent microglial activation plays a critical role in chronic neuroinflammation post-TBI. Given the bidirectional communication along the brain–gut axis, it is plausible to suppose that gut microbiota dysbiosis post-TBI influences microglial activation. In the present study, hippocampal microglial activation was observed at 7 days and 28 days post-TBI. However, in TBI mice with a depletion of gut microbiota, microglia were activated at 7 days post-TBI, but not at 28 days post-TBI, indicating that gut microbiota contributes to the long-term activation of microglia post-TBI. In addition, in conventional mice colonized by the gut microbiota of TBI mice using fecal microbiota transplant (FMT), microglial activation was observed at 28 days post-TBI, but not at 7 days post-TBI, supporting the role of gut microbiota dysbiosis in persistent microglial activation post-TBI. The RNA sequencing of the hippocampus identified a microglial activation gene, Lyz2, which kept upregulation post-TBI. This persistent upregulation was inhibited by oral antibiotics and partly induced by FMT. 16s rRNA gene sequencing showed that the composition and function of gut microbiota shifted over time post-TBI with progressive dysbiosis, and untargeted metabolomics profiling revealed that the tryptophan metabolic phenotype was differently reshaped at 7 days and 28 days post-TBI, which may play a role in the persistent upregulation of Lyz2 and the activation of microglia. This study implicates that gut microbiota and Lyz2 are potential targets for the development of novel strategies to address persistent microglial activation and chronic neuroinflammation post-TBI, and further investigations are warranted to elucidate the specific mechanism.

22 November 2024 in Advanced Science
Verified
Journal Article
Open access
YZYu Zhang
Yu Zhang
XLXin Li
Xin Li
HCHuiyan Chen
Huiyan Chen
JLJiawei Li
Jiawei Li
XGXiaohuan Guo
Xiaohuan Guo
ZWZhen Wang
Zhen Wang
Hepatocellular carcinoma (HCC) mainly depends on liver fibrosis/cirrhosis, which is regulated by tumor cells and the tumor microenvironment (TME), and is a crucial factor in tumor progression. This study aimed to identify abnormally expressed miR‐500a‐3p in the hepatitis‐cirrhosis‐HCC pathway and explored the roles of miR‐500a‐3p in HCC progression. A clinical cohort of patients with HCC is studied retrospectively. Subsequently, the role of miR‐500a‐3p transported by HCC exosomes in hepatic stellate cell (HSC) activation, hepatoma growth and invasion, and immune cell differentiation is determined by in vitro and in vivo experiments. In clinical tissues, miR‐500a‐3p is significantly enriched in HCC and cirrhosis tissues, and co‐expression of the immune marker CD4 or PD‐L1 significantly correlates with low survival rates in patients. Extracellular miR‐500a‐3p is taken up by HSC and PBMC, which promotes the secretion of the cytokines TGF‐β1 and IL‐10, increases PD‐L1 expression in HSC, and stabilizes PD‐1 expression in PBMC to affect the TME. Moreover, miR‐500a‐3p is associated with CD4+ T‐cell exhaustion and Treg differentiation and is significantly associated with increased tumorigenicity in in situ mouse HCC models. Mechanistically, HCC‐derived exosomal miR‐500a‐3p directly influences SOCS2 to regulate the JAK3/STAT5A/STAT5B signaling pathway. MiR‐500a‐3p promotes the growth and migration of HCC through the SOCS2/JAK3/STAT5A/STAT5B axis.

1 December 2021 in Photodiagnosis and Photodynamic Therapy
Verified
Journal Article
Closed access
YHYingnan Hu
Yingnan Hu
TFTianxiao Fu
Tianxiao Fu
ZZZhe Zhang
Zhe Zhang
LHLin Hua
Lin Hua
QZQiming Zhao
Qiming Zhao
WZWei Zhang
Wei Zhang